GlassScriptPhysician profile
Rachael Bator
NPI 1093201618
$2,210.41
in general payments reported to CMS, 2019-2025
18 companies · $40.71 in 2025
The $40.71 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $129 · 2022: $783 · 2023: $737 · 2024: $520 · 2025: $40.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $579.37 | 2021-2025 | |
| Novo Nordisk INC | $433.36 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $376.36 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $187.11 | 2022 | |
| Merck Sharp & Dohme LLC | $109.66 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Pfizer INC. | $97.96 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.18 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $58.71 | 2023-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $57.23 | 2022-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $45.97 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $38.84 | 2023-2024 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $32.87 | 2021 | |
| Exact Sciences Corporation | $32.10 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $29.77 | 2022-2024 | Shingrix, Arexvy |
| Sanofi Pasteur INC. | $22.00 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.41 | 2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.06 | 2023 | Tradjenta, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachael Bator listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.